IP Library Granted Patent US 10,973,953
Granted Patent B1
US 10,973,953 · App. 15/680,012 · Granted Apr 13, 2021

Methods and compositions for preparing transplant tissue

Inventors: Eric Semler (Morganville, NJ); Mark Spilker (Kilchberg, CH); Kevin Wu (Morganville, NJ); Yen-Chen Huang (East Brunswick, NJ); Evangelia Chnari (Scotch Plains, NJ); Jeffrey Cartmell (Freehold, NJ); Morris Jacobs (Newtown, PA); Alison Ling (Piscataway, NJ); Moon Hae Sunwoo (Old Tappan, NJ)
Assignee: Musculoskeletal Transplant Foundation
A61L27/3895A01N1/0284A61L27/3604A61L27/3683A61L27/38A61L2430/02
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,973,953
App. No.
15/680,012
Granted
Apr 13, 2021
Kind
B1
Abstract

Methods and compositions for preparing and priming a tissue graft for an accelerated therapeutic effect are provided herein. In one embodiment, the method includes obtaining a tissue containing viable cells from a donor, wherein the viable cells are endogenous to the tissue and remain resident in the tissue; and priming the viable cells with one or more stimuli to produce a primed tissue, wherein when grafted to a recipient the primed tissue provides a benefit compared to non-primed tissue.

Claims (11)

1. An artificially primed tissue graft, comprising:

a tissue obtained from a donor; and

viable cells that are endogenous to the tissue and remain resident in the tissue, wherein the viable cells have been primed with one or more stimuli comprising simulated hypoxia to produce the artificially primed tissue graft,

wherein when used to treat a patient the artificially primed tissue graft provides a benefit compared to non-primed tissue, said benefit comprising an increased amount of angiogenic growth factors in the artificially primed tissue graft, wherein the angiogenic growth factors comprise epidermal growth factor (EGF), hepatocyte growth factor (HGF), and placental growth factor (PGF).

2. The artificially primed tissue graft of claim 1 , wherein the simulated hypoxia was induced by exposing the tissue and resident endogenous viable cells to a medium ingredient that simulates hypoxia, or both.

3. The artificially primed tissue graft of claim 1 , wherein the medium ingredient comprises deferoxamine.

4. The artificially primed tissue graft of claim 1 , wherein exposure to simulated hypoxia occurred for a period of time from about 5 hour to about 100 hours.

5. The artificially primed tissue graft of claim 4 , wherein said period of time is from about 20 hours to about 100 hours.

6. The artificially primed tissue graft of claim 4 , wherein said period of time is from about 20 hours to about 30 hours.

7. The artificially primed tissue graft of claim 1 , wherein the tissue obtained from a donor comprises placental tissue.

8. The artificially primed tissue graft of claim 7 , wherein the placental tissue comprises amnion tissue.

Assignments (4)
SECURITY INTEREST Recorded Jul 27, 2023
From: MUSCULOSKELETAL TRANSPLANT FOUNDATION, INC.
To: M&T BANK
Reel/Frame 064401/0369 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 20, 2017
From: SUNWOO, MOON HAE
To: MUSCULOSKELETAL TRANSPLANT FOUNDATION
Reel/Frame 044181/0125 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 20, 2017
From: CARTMELL, JEFFREY; JACOBS, MORRIS; SEMLER, ERIC; CHNARI, EVANGELIA; HUANG, YEN-CHEN; LING, ALISON; WU, KEVIN
To: MUSCULOSKELETAL TRANSPLANT FOUNDATION
Reel/Frame 044181/0146 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 20, 2017
From: SPILKER, MARK
To: MUSCULOSKELETAL TRANSPLANT FOUNDATION
Reel/Frame 044181/0198 →
Continuity (1)
Provisional Application 62376843 · Aug 18, 2016
Cited By (1)
US 12,275,954